Skip to main content
Clinical Trials/ACTRN12610000389000
ACTRN12610000389000Completed未知

The feasibility and preliminary clinical utility of 11C-Methionine and 18F-Fluorothymidine Positron Emission Tomography-Computerised Tomography (PET-CT) imaging following radiotherapy and 2-3 cycles of adjuvant chemotherapy in patients with high grade glioma in order to assess time to progression, overall survival and 6 month progression-free survival.

Sir Charles Gairdner Hospital0 sites30 target enrollmentStarted: May 13, 2010Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • Histologically confirmed malignant glioma (grades III-IV), Received surgical biopsy or debulking, radiotherapy, and commenced adjuvant chemotherapy with a temozolomide-containing chemotherapy regimen, Planned for routine MRI following 2 or 3 cycles of adjuvant chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, able to undertake MRI and PET-CT imaging, written informed consent.

Exclusion Criteria

  • Pregnancy, age less than 18 years, Medical contraindication to MRI or PET-CT imaging, Cognitive impairment considered to impair the ability to give written informed consent in the opinion of the treating clinician

Investigators

Similar Trials